|
|
|
|
|||||
|
|
|
The company's lead drug candidate is in a phase 3 trial, and enrollment is progressing well.
The drug is also being tested in oral formulation, and there's plenty of value in Viking's pipeline.
In common with many other small-cap biotech stocks, Viking Therapeutics' (NASDAQ: VKTX) share price tends to be volatile as investors react to the ebb and flow of news from the company. Today was an up day with the stock rising more than 10% by 12:30 p.m. ET.
The move comes on the day the company released its third-quarter earnings report and updated the market on the progress of its clinical trials.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
The company's lead drug candidate, VK2735 (obesity), is being trialled in subcutaneous (injectable) and oral form, with a phase 3 study underway in its subcutaneous form. Management reported that enrollment in the phase 3 "Vanquish" trial is going well, with CEO Brian Lian noting that enrollment was "maybe a little ahead of schedule" on the earnings call.
VK2735 in oral form is a bit more complicated, not least because investors were left disappointed by the safety and tolerability data from the top-line results of a phase 2 trial reported earlier in the year -- the efficacy results were satisfactory, though. However, the story isn't quite over for the oral formulation, as the biotech company's management recently announced a phase 1 trial to explore weekly subcutaneous dosing, followed by maintenance dosing with either the oral or subcutaneous form.
Image source: Getty Images.
In addition, according to the earnings release, "Viking plans to meet with regulatory authorities in the fourth quarter to discuss next steps with oral VK2735."
These developments are positive and indicate that there's plenty of value left in Viking's pipeline, which is what buoyed investors today.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $602,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,092!*
Now, it’s worth noting Stock Advisor’s total average return is 1,028% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 20, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
| 4 hours | |
| 4 hours | |
| 8 hours | |
| 9 hours | |
| 9 hours |
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies
VKTX +7.96%
Investor's Business Daily
|
| Oct-22 | |
| Oct-22 | |
| Oct-21 | |
| Oct-20 | |
| Oct-17 | |
| Oct-17 | |
| Oct-17 | |
| Oct-17 | |
| Oct-17 | |
| Oct-16 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite